<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="9778AFDE-01AE-49DF-E7AB-D25D89711602" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Human Prescription Drug Label" />
<title mediaType="text/x-hl7-title+xml">ENDURONYL&#174;<br />(methyclothiazide and deserpidine)<br />tablets<br />oral
thiazide-rauwolfia therapy for hypertension.</title>
<effectiveTime value="20060510" />
<setId root="9778AFDE-01AE-49DF-E7AB-D25D89711602" />
<versionNumber value="2" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Abbott Laboratories</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="09D8F5D4-ACA1-9D9E-FE2D-F7C5BB7BC832" />
<effectiveTime value="20060510" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0074-6838" codeSystem="2.16.840.1.113883.6.69" />
<name>ENDURONYL</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="5" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="L3H46UAC61" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>methyclothiazide</name>
<activeMoiety>
<activeMoiety>
<code code="L3H46UAC61" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>methyclothiazide</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="0.25">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="0.25" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9016E3VB47" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>deserpidine</name>
<activeMoiety>
<activeMoiety>
<code code="9016E3VB47" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>deserpidine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>METHYCLOTHIAZIDE AND DESERPIDINE</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>D&amp;C Yellow No. 10</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Yellow No. 6</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>magnesium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>talc</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0074-6838-01" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48350" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SQUARE" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">LS</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="true" xsi:type="BL" />
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0074-6854" codeSystem="2.16.840.1.113883.6.69" />
<name>ENDURONYL FORTE </name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="5" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="L3H46UAC61" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>methyclothiazide</name>
<activeMoiety>
<activeMoiety>
<code code="L3H46UAC61" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>methyclothiazide</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="0.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="0.5" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9016E3VB47" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>deserpidine</name>
<activeMoiety>
<activeMoiety>
<code code="9016E3VB47" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>deserpidine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>METHYCLOTHIAZIDE AND DESERPIDINE</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>iron oxide</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>magnesium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>talc</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0074-6854-01" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48324" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAY" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48350" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SQUARE" xsi:type="CE" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">LT</value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="true" xsi:type="BL" />
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="F3AA8E7A-A4CF-FCB8-2282-FA46089B684A" />
<code code="34066-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="BOXED WARNING section" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph><content styleCode="bold">WARNING:</content><br />This
fixed combination drug is not indicated for initial therapy of hypertension.
 Hypertension requires therapy titrated to the individual patient.  If the
fixed combination represents the dosage so determined, its use may be more
convenient in patient management.  The treatment of hypertension is not static,
but must be reevaluated as conditions in each patient warrant.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="2CF29C14-1EAE-4E8A-FE69-DF9923EE446F" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION section" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>ENDURONYL tablets are an orally administered combination
of Enduron<sup>&#174;</sup> (methyclothiazide) and deserpidine.  ENDURONYL
tablets are available in two dosage strengths.  ENDURONYL tablets contain
methyclothiazide 5 mg and deserpidine 0.25&#160;mg.  ENDURONYL FORTE tablets
contain methyclothiazide 5 mg and deserpidine 0.5 mg.</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="2F462868-0BBF-3836-79BA-BD9C70FDF6C2" />
<title mediaType="text/x-hl7-title+xml">Inactive Ingredients</title>
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="6CB18EDF-31AD-8014-09BE-6D72C2A87E88" />
<title mediaType="text/x-hl7-title+xml">ENDURONYL Tablets</title>
<text><paragraph>Corn starch, D&amp;C Yellow No. 10, FD&amp;C Yellow
No. 6, lactose, magnesium stearate and talc.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="2B9E6C6A-3E5C-49EF-DB89-A15988C6F318" />
<title mediaType="text/x-hl7-title+xml">ENDURONYL FORTE Tablets</title>
<text><paragraph>Corn starch, iron oxide, lactose, magnesium stearate
and talc.</paragraph><paragraph>Methyclothiazide is an oral diuretic-antihypertensive
of the benzothiadiazine (thiazide) class of drugs.  It occurs as a white to
practically white crystalline powder which is basically odorless and has a
molecular weight of 360.25.  Methyclothiazide is very slightly soluble in
water and chloroform, and slightly soluble in alcohol.  Chemically, methyclothiazide
is represented as 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide
1,1-dioxide.</paragraph><paragraph>Deserpidine is a purified rauwolfia
alkaloid.  It occurs as a white to light yellow crystalline powder and has
a molecular weight of 578.64.  Deserpidine is insoluble in water and very
slightly soluble in alcohol.  Chemically, deserpidine is identified as 17&#945;-methoxy-18&#946;-[(3,4,5-trimethoxybenzoyl)oxy]-3&#946;,20&#945;-yohimban-16&#946;-carboxylic
acid methyl ester.  The structural formulas are:</paragraph><paragraph /><table border="0" cellpadding="0" cellspacing="1"><colgroup>
<col />
<col />
</colgroup>
<tbody>
<tr><td align="center" colspan="2"><renderMultiMedia referencedObject="MM1127427244-1" /></td></tr>
<tr><td align="center">Methyclothiazide</td><td align="center">Deserpidine</td></tr>
</tbody>
</table></text>
<effectiveTime value="20060510" />
<component>
<observationMedia ID="MM1127427244-1">
<id root="41FE3136-4171-4AD1-0EB2-D37F6CC07828" />
<value mediaType="image/jpeg" xsi:type="ED"><reference value="enduronyl-structure.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="58B9AA4A-7EF9-2AC5-D9FD-46DC003493B7" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Clinical Pharmacology" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text><paragraph>The combined antihypertensive actions of methyclothiazide
and deserpidine result in a total clinical antihypertensive effect which is
greater than can ordinarily be achieved by either drug given individually.</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="6E83DCD0-5FF8-978C-B0D9-7D6BF3CCEA5F" />
<title mediaType="text/x-hl7-title+xml">Methyclothiazide</title>
<text><paragraph>The diuretic and saluretic effects of methyclothiazide
result from a drug-induced inhibition of the renal tubular reabsorption of
electrolytes.  The excretion of sodium and chloride is greatly enhanced. 
Potassium excretion is also enhanced to a variable degree, as it is with the
other thiazides.  Although urinary excretion of bicarbonate is increased slightly,
there is usually no significant change in urinary pH.  Methyclothiazide has
a per mg natriuretic activity approximately 100 times that of the prototype
thiazide, chlorothiazide.  At maximal therapeutic dosages, all thiazides are
approximately equal in their diuretic/natriuretic effects.</paragraph><paragraph>There is significant natriuresis and diuresis within 2 hours
after administration of a single dose of methyclothiazide.  These effects
reach a peak in about 6 hours and persist for 24&#160;hours following oral
administration of single dose.</paragraph><paragraph>Like other benzothiadiazines,
methyclothiazide also has antihypertensive properties, and may be used for
this purpose either alone or to enhance the antihypertensive action of other
drugs.  The mechanism by which the benzothiadiazines, including methyclothiazide,
produce a reduction of elevated blood pressure is not known.  However, sodium
depletion appears to be involved.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="AD33AF86-DAB7-BBB2-B235-DF4234005520" />
<title mediaType="text/x-hl7-title+xml">Deserpidine</title>
<text><paragraph>The pharmacologic actions of deserpidine are essentially
the same as those of other active rauwolfia alkaloids.  Deserpidine probably
produces its antihypertensive effects through depletion of tissue stores of
catecholamines (epinephrine and norepinephrine) from peripheral sites.  By
contrast, its sedative and tranquilizing properties are thought to be related
to depletion of 5-hydroxytryptamine from the brain.  The antihypertensive
effect is often accompanied by bradycardia.  There is no significant alteration
in cardiac output or renal blood flow.  The carotid sinus reflex is inhibited,
but postural hypotension is rarely seen with the use of conventional doses
of deserpidine alone.</paragraph><paragraph>Deserpidine, like other
rauwolfia alkaloids, is characterized by slow onset of action and sustained
effect which may persist following withdrawal of the drug.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="A055CCC4-F795-056E-41A5-4CFB839C9569" />
<title mediaType="text/x-hl7-title+xml">Pharmacokinetics and Metabolism</title>
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="422FEC7C-8FAE-34D9-B108-D37B3CC3A400" />
<title mediaType="text/x-hl7-title+xml">Methyclothiazide</title>
<text><paragraph>Methyclothiazide is rapidly absorbed and slowly
eliminated by the kidneys as intact drug but primarily as an inactive metabolite.
 Additional information on the pharmacokinetics is not known at this time.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="50903425-A865-A9DE-8D4D-59C4CBF88CE2" />
<title mediaType="text/x-hl7-title+xml">Deserpidine</title>
<text><paragraph>Information is limited on the human pharmacokinetics
of the rauwolfia alkaloids.  Rauwolfia alkaloids appear to be widely distributed
in body tissues, especially adipose tissue.  They also cross the blood-brain
barrier.  Rauwolfia alkaloids are extensively metabolized.  The unchanged
alkaloid and the metabolites are excreted slowly in urine and feces.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="21FFF121-1E9F-7DFC-0F1D-A1FC650149DA" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Indications and Usage" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph>ENDURONYL (methyclothiazide and deserpidine) is indicated
in the treatment of mild to moderately severe hypertension (see <content styleCode="bold">BOXED
WARNING</content>).  In many cases ENDURONYL tablets alone produces an adequate
reduction of blood pressure.  In resistant or unusually severe cases ENDURONYL
tablets also may be supplemented with more potent antihypertensive agents.
 When administered with ENDURONYL tablets, more potent agents can be given
at reduced dosage to minimize undesirable side effects.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="3179759B-ECED-570E-5A42-A6CF7D913E45" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS section" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>Methyclothiazide is contraindicated in patients with
anuria and in patients with a history of hypersensitivity to this or other
sulfonamide-derived drugs.</paragraph><paragraph>Deserpidine is contraindicated
in patients with known hypersensitivity, history of mental depression especially
with suicidal tendencies, active peptic ulcer, and ulcerative colitis.  It
is also contraindicated in patients receiving electroconvulsive therapy.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="12A29382-E912-A3FF-2636-1351CB1FB39C" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS section" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text />
<effectiveTime value="20060510" />
<component>
<section>
<id root="2E5F86BC-9744-A977-6247-AD9D90E4B9F4" />
<title mediaType="text/x-hl7-title+xml">Methyclothiazide</title>
<text><paragraph>Methyclothiazide shares with other thiazides the
propensity to deplete potassium reserves to an unpredictable degree.</paragraph><paragraph>There have been isolated reports that certain nonedematous
individuals developed severe fluid and electrolyte derangements after only
brief exposure to normal doses of thiazide and nonthiazide diuretics.</paragraph><paragraph>Thiazides should be used with caution in patients with renal
disease or significant impairment of renal function, since azotemia may be
precipitated and cumulative drug effects may occur.</paragraph><paragraph>Thiazides
should be used with caution in patients with impaired hepatic function or
progressive liver disease, since minor alterations of fluid and electrolyte
balance may precipitate hepatic coma.</paragraph><paragraph>Sensitivity
reactions may occur in patients with a history of allergy or bronchial asthma.</paragraph><paragraph>The possibility of exacerbation or activation of systemic
lupus erythematosus has been reported.</paragraph><paragraph>Hyperuricemia
may occur or frank gout may be precipitated in certain patients receiving
thiazide therapy.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="D5A41311-88E1-6969-F5CA-914629F80D54" />
<title mediaType="text/x-hl7-title+xml">Deserpidine</title>
<text><paragraph>Deserpidine differs slightly in chemical structure
from reserpine; however, its actions, indications, cautions, and adverse reactions
are common to the class of rauwolfia alkaloids.  Reserpine may cause mental
depression.  Recognition of depression may be difficult because this condition
may often be disguised by somatic complaints (Masked Depression).  The drug
should be discontinued at first signs of depression such as despondency, early
morning insomnia, loss of appetite, impotence, or self-deprecation.  Drug-induced
depression may persist for several months after drug withdrawal and may be
severe enough to result in suicide.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="52C8CF06-5D27-C386-4B62-05157060801B" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Precautions" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text />
<effectiveTime value="20060510" />
<component>
<section>
<id root="3E233FC2-55AD-4A27-4073-E8ACAB8DA275" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="General Precautions" />
<title mediaType="text/x-hl7-title+xml">General</title>
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="BB41C91C-AD13-70A3-8703-BFE6FC4B24CF" />
<title mediaType="text/x-hl7-title+xml">Methyclothiazide</title>
<text><paragraph>All patients should be observed for other clinical
signs of electrolyte imbalances such as dryness of mouth, thirst, weakness,
lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue,
hypotension, oliguria, tachycardia, and gastrointestinal disturbances such
as nausea and vomiting.</paragraph><paragraph>Hypokalemia may develop,
especially with brisk diuresis, when severe cirrhosis is present, during concomitant
use of corticosteroids or ACTH, or after prolonged therapy.</paragraph><paragraph>Interference with adequate oral electrolyte intake will
also contribute to hypokalemia.  Hypokalemia may be avoided or treated with
the intake of potassium supplements or foods containing a high potassium content.</paragraph><paragraph>Any chloride deficit is generally mild and usually does
not require specific treatment except under extraordinary circumstances (as
in liver disease or renal disease).  Dilutional hyponatremia may occur in
endematous patients in hot weather.  Appropriate therapy is water restriction
rather than administration of salt, except in rare instances when the hyponatremia
is life threatening.  In actual salt depletion, appropriate replacement is
the therapy of choice.</paragraph><paragraph>Latent diabetes mellitus
may become manifest during thiazide administration.</paragraph><paragraph>The
antihypertensive effects of the drug may be enhanced in the postsympathectomy
patient.</paragraph><paragraph>If progressive renal impairment
becomes evident as indicated by a rising-nonprotein nitrogen or blood urea
nitrogen, a careful reappraisal of therapy is necessary with consideration
given to withholding or discontinuing diuretic therapy.</paragraph><paragraph>Thiazide diuretics have been shown to increase the urinary
excretion of magnesium; this may result in hypomagnesemia.</paragraph><paragraph>Thiazides may decrease urinary calcium excretion and may
cause intermittent and slight elevation of serum calcium in the absence of
known disorders of calcium metabolism.  Marked hypercalcemia may be evidence
of hidden hyperparathyroidism.  Thiazides should be discontinued before carrying
out tests for parathyroid function.</paragraph><paragraph>Thiazides
may cause increased concentrations of total serum cholesterol, total triglycerides,
and low-density lipoproteins in some patients.  Use thiazides with caution
in patients with moderate or high cholesterol concentrations and in patients
with elevated triglyceride levels.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="8B78A151-71EF-5E3D-E993-FD3F23428567" />
<title mediaType="text/x-hl7-title+xml">Deserpidine</title>
<text><paragraph>Because rauwolfia preparations increase gastrointestinal
motility and secretion, this drug should be used cautiously in patients with
a history of peptic ulcer, ulcerative colitis, or gallstones, where biliary
colic may be precipitated.</paragraph><paragraph>Caution should
be exercised when treating hypertensive patients with renal insufficiency,
since they adjust poorly to lowered blood pressure levels.</paragraph><paragraph>Preoperative withdrawal of deserpidine does not assure that
circulatory instability will not occur.  It is important that the anesthesiologist
be aware of the patient's drug intake and consider this in the overall
management, since hypotension has occurred in patients receiving rauwolfia
preparations.  Anticholinergic and/or adrenergic drugs (metaraminol, norepinephrine)
have been employed to treat adverse vagocirculatory effects.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="1D48A1E4-3C9A-1866-FEA0-EBC41AF799BC" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Information for Patients section" />
<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
<text><paragraph>Patients should inform their doctor if they have:
 1) had an allergic reaction to methyclothiazide, other diuretics, or deserpidine;
2) asthma; 3) kidney disease; 4) liver disease; 5) gout; 6) systemic lupus
erythematosus; or 7) been taking other drugs such as cortisone, digitalis,
lithium carbonate, or drugs for diabetes.</paragraph><paragraph>The
physician should inform patients of possible side effects and caution the
patient to report any of the following symptoms of electrolyte imbalance:
 dryness of mouth, thirst, weakness, tiredness, drowsiness, restlessness,
muscle pains or cramps, nausea, vomiting, or increased heart rate.</paragraph><paragraph>The patient and his family should be warned of the possibility
of depression.  If signs of despondency, early morning insomnia, loss of appetite,
impotence, or self-deprecation appear, the drug should be discontinued and
the physician consulted.</paragraph><paragraph>Patients who engage
in potentially hazardous activities such as operating machinery or driving
motor vehicles should be warned about possible central nervous system (CNS)
side effects.</paragraph><paragraph>The physician should advise the
patient to take this medication every day as directed. Physicians should also
caution patients that drinking alcohol can increase the chance of dizziness
and other CNS-depressant effects.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="8D203999-4244-A385-CBC3-9B36F02F0DA6" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Laboratory Tests section" />
<title mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
<text><paragraph>Initial and periodic determination of serum electrolytes
should be performed at appropriate intervals for the purpose of detecting
possible electrolyte imbalances such as hyponatremia, hypochloremic alkalosis,
and hypokalemia.  Serum and urine electrolyte determinations are particularly
important when a patient is vomiting excessively or receiving parenteral fluids.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="05C769A2-A30A-0455-FBB4-9738F1ED50D1" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Interactions section" />
<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="EEA65FB9-2100-5D2A-67E5-AD10B0DEF1E1" />
<title mediaType="text/x-hl7-title+xml">Methyclothiazide</title>
<text><paragraph>Hypokalemia can sensitize or exaggerate the response
of the heart to the toxic effects of <content styleCode="italics">digitalis</content> (e.g., increased ventricular irritability).</paragraph><paragraph>Hypokalemia may develop during concomitant use of <content styleCode="italics">steroids  </content> or <content styleCode="italics">ACTH</content>.</paragraph><paragraph><content styleCode="italics">Insulin</content> requirements in diabetic patients may be increased, decreased,
or unchanged.</paragraph><paragraph>Thiazides may decrease arterial
responsiveness to <content styleCode="italics">norepinephrine</content>. 
This diminution is not sufficient to preclude effectiveness of the pressor
agent for therapeutic use.</paragraph><paragraph><content styleCode="italics">Non-steroidal
Anti-inflammatory Drugs</content>&#8211; In some patients the administration
of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic,
and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
 Therefore, when Enduronyl tablets and non-steroidal anti-inflammatory agents
are used concomitantly, the patient should be observed closely to determine
if the desired effect of the diuretic is obtained.</paragraph><paragraph>Thiazide
drugs may increase the responsiveness to <content styleCode="italics">tubocurarine</content>.</paragraph><paragraph><content styleCode="italics">Lithium</content> renal clearance is reduced by thiazides, increasing the risk of
lithium toxicity.</paragraph><paragraph>Thiazides may add to or
potentiate the action of <content styleCode="italics">other antihypertensive
drugs</content>.  Potentiation occurs with ganglionic or peripheral adrenergic
blocking drugs.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="9A07E68D-DAF5-E841-82A7-49C71AB009ED" />
<title mediaType="text/x-hl7-title+xml">Deserpidine</title>
<text><paragraph>Use deserpidine cautiously with <content styleCode="italics">digitalis</content> and <content styleCode="italics">quinidine</content> since cardiac
arrhythmias have occurred with rauwolfia preparations.</paragraph><paragraph>Hypotensive effects of rauwolfia alkaloids may be enhanced when
used concurrently with other <content styleCode="italics">antihypertensive
agents</content>, <content styleCode="italics">diuretics</content>, or <content styleCode="italics">phenothiazine derivatives</content>, therefore, careful
titration of dosage is necessary.</paragraph><paragraph>Additive
CNS-depressant effects can occur when rauwolfia alkaloids are taken concomitantly
with other <content styleCode="italics">CNS-depressant agents</content> or <content styleCode="italics">alcohol</content>.</paragraph><paragraph><content styleCode="italics">Monoamine oxidase inhibitors</content> should be avoided
or used with extreme caution.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="CB1DCCB6-45B0-51A3-CC62-6F2090016081" />
<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug/Laboratory Test Interactions section" />
<title mediaType="text/x-hl7-title+xml">Drug/Laboratory Test Interactions</title>
<text><paragraph>Thiazides may decrease serum PBI levels without
signs of thyroid disturbance.</paragraph><paragraph>Thiazides should
be discontinued before carrying out tests for parathyroid function.</paragraph><paragraph>Rauwolfia alkaloids have been reported to interfere with
assay procedures for the determination of urinary 17-hydroxycorticosteroids
and 17-ketosteroids.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="0247A539-37DF-42BD-660F-25593A82285F" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Carcinogenesis, Mutagenesis, Impairment of Fertility section" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
<text><paragraph>No long-term data are available for methyclothiazide
or deserpidine concerning the potential for carcinogenicity.  No adequate
studies have been done to determine the mutagenic potential of methyclothiazide
or deserpidine, or their effects on fertility.</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="0CF591B7-A30D-13B3-D3C5-2F4314FCF57B" />
<title mediaType="text/x-hl7-title+xml">Animal Tumorigenicity</title>
<text><paragraph>Although there are no studies demonstrating that
deserpidine is an animal tumorigen, it is a prolactin stimulator and structurally
related to reserpine.  Rodent studies have shown that reserpine is an animal
tumorigen, causing an increased incidence of mammary fibroadenomas in female
mice, malignant tumors of the seminal vesicles in male mice, and malignant
adrenal medullary tumors in male rats.  These findings arose in 2 year studies
in which the drug was administered in the feed at concentrations of 5 and
10&#160;ppm - about 100 to 300 times the usual human dose.  The breast neoplasms
are thought to be related to reserpine's prolactin-elevating effect.
 Several other prolactin-elevating drugs have also been associated with an
increased incidence of mammary neoplasia in rodents.</paragraph><paragraph>The extent to which these findings indicate a risk to humans is
uncertain.  Tissue culture experiments show that about one-third of human
breast tumors are prolactin-dependent <content styleCode="italics">in vitro</content>, a factor of considerable importance if the use of the drug is
contemplated in a patient with previously detected breast cancer.  The possibility
of an increased risk of breast cancer in reserpine users has been studied
extensively; however, no firm conclusion has emerged.  Although a few epidemiologic
studies have suggested a slightly increased risk (less than two fold in all
studies except one) in women who have used reserpine, other studies of generally
similar design have not confirmed this.  Epidemiologic studies conducted using
other drugs (neuroleptic agents) that, like reserpine, increase prolactin
levels and, therefore, would be considered rodent mammary carcinogens, have
not shown an association between chronic administration of the drug and human
mammary tumorigenesis.  While long-term clinical observation has not suggested
such an association, the available evidence is considered too limited to be
conclusive at this time.  An association of reserpine intake with pheochromocytoma
or tumors of the seminal vesicles has not been explored.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="1A64A3E4-E1AC-18A1-A7FE-1EC16A8A57D2" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pregnancy section" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="67EBB793-7C4B-06EF-50C2-54732EFB312A" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Teratogenic Effects section" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph /></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="64DFA168-9B62-120A-7504-AA4681346317" />
<title mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text><paragraph>Animal reproduction studies have not been conducted
with methyclothiazide or deserpidine.  It is also not known whether methyclothiazide
or deserpidine can cause fetal harm when administered to a pregnant woman.
 Methyclothiazide and deserpidine should be given to a pregnant woman only
if clearly needed.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="E51A5994-C0E9-3A31-D33D-FE194B19253B" />
<code code="34078-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nonteratogenic Effects section" />
<title mediaType="text/x-hl7-title+xml">Nonteratogenic Effects</title>
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="AC0A85F8-E6ED-1E40-9508-669A102CC832" />
<title mediaType="text/x-hl7-title+xml">Methyclothiazide</title>
<text><paragraph>Thiazides cross the placental barrier and appear
in cord blood.  The use of thiazides in pregnant women requires that the anticipated
benefit be weighed against possible hazards to the fetus.  These hazards include
fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions
that have occurred in the adult.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="46B99F58-750A-F99A-31D0-EFE087D95115" />
<title mediaType="text/x-hl7-title+xml">Deserpidine</title>
<text><paragraph>Rauwolfia alkaloids are known to cross the placental
barrier, to enter the fetal circulation, and to appear in cord blood.  Increased
respiratory secretions, nasal congestion, cyanosis and anorexia may occur
in neonates of rauwolfia alkaloid-treated mothers.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="DCAB2C02-A97A-3520-2675-E6661B7F6738" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nursing Mothers section" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph>Methyclothiazide and deserpidine are excreted in
human milk.  Because of the potential for serious adverse reactions in nursing
infants from ENDURONYL tablets, a decision should be made whether to discontinue
nursing or to discontinue the drug taking into account the importance of the
drug to the mother.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="867077E6-2552-1F40-D8FB-C2E6F79FAC5F" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pediatric Use section" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>Safety and effectiveness in children have not been
established.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="08FB6333-D978-3448-7F41-E037D7C074BB" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS section" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph>Adverse reactions are usually reversible upon reduction
of dosage or discontinuation of ENDURONYL tablets.  Whenever adverse reactions
are moderate or severe, it may be necessary to discontinue the drug.</paragraph><paragraph>The following adverse reactions have been observed, but there
has not been enough systematic collection of data to support an estimate of
their frequency.  Consequently, the reactions are categorized by organ system
and are listed in decreasing order of severity and not frequency.</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="1F19C7F8-DDFA-EA17-0FDF-FEDF655A34CB" />
<title mediaType="text/x-hl7-title+xml">Methyclothiazide</title>
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="E3B0DCFD-6C92-F2A3-05E1-93B6C13476D2" />
<title mediaType="text/x-hl7-title+xml">Body as a Whole</title>
<text><paragraph>Headache, cramping, weakness.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="A59D5100-8421-359D-5FB2-5EF7CAC460ED" />
<title mediaType="text/x-hl7-title+xml">Cardiovascular System</title>
<text><paragraph>Orthostatic hypotension (may be potentiated by
alcohol, barbiturates, or narcotics).</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="755FFD44-ED15-BE0B-10CE-D3885B5D45CF" />
<title mediaType="text/x-hl7-title+xml">Digestive System</title>
<text><paragraph>Pancreatitis, jaundice (intrahepatic cholestatic),
sialadenitis, vomiting, diarrhea, nausea, gastric irritation, constipation,
anorexia.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="325A35CA-534F-94FC-684C-5EBE547AF928" />
<title mediaType="text/x-hl7-title+xml">Hemic and Lymphatic System</title>
<text><paragraph>Aplastic anemia, hemolytic anemia, agranulocytosis,
leukopenia, thrombocytopenia.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="2B2B8120-1BD7-9FC2-4BED-24002CAFB801" />
<title mediaType="text/x-hl7-title+xml">Hypersensitivity Reactions</title>
<text><paragraph>Anaphylactic reactions, necrotizing angiitis (vasculitis,
cutaneous vasculitis), Stevens-Johnson syndrome, respiratory distress (including
pneumonitis and pulmonary edema), fever, purpura, urticaria, rash, photosensitivity.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="154C9CCC-E7A3-42E0-9C86-E61DD8E86A3D" />
<title mediaType="text/x-hl7-title+xml">Metabolic and Nutritional Disorders</title>
<text><paragraph>Hyperglycemia, hyperuricemia, electrolyte imbalance
(see <content styleCode="bold">PRECAUTIONS</content>), hypercalcemia.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="E57D0614-2455-20E2-AAB8-6175D485B8B7" />
<title mediaType="text/x-hl7-title+xml">Nervous System</title>
<text><paragraph>Vertigo, dizziness, paresthesias, muscle spasm,
restlessness.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="84180D97-88BD-DC74-D8DF-E1F65BC47255" />
<title mediaType="text/x-hl7-title+xml">Special Senses</title>
<text><paragraph>Transient blurred vision, xanthopsia.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="85F934E1-7F1A-FDE6-661F-99BD0E7AE224" />
<title mediaType="text/x-hl7-title+xml">Urogenital System</title>
<text><paragraph>Glycosuria.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="0041AC61-A672-A6A3-AD4C-E62C2FBA1DDD" />
<title mediaType="text/x-hl7-title+xml">Deserpidine</title>
<text><paragraph /></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="7B36A51A-7A35-EAD4-83C2-EB31438927FA" />
<title mediaType="text/x-hl7-title+xml">Body as a Whole</title>
<text><paragraph>Headache.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="A436E5B1-1039-19EB-CCD9-3D3134699955" />
<title mediaType="text/x-hl7-title+xml">Cardiovascular System</title>
<text><paragraph>Arrhythmias (particularly when used concurrently
with digitalis or quinidine), syncope, angina-like symptoms, bradycardia,
fluid retention.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="F3D77AEE-5C66-4BF6-A36A-026336E27C17" />
<title mediaType="text/x-hl7-title+xml">Digestive System</title>
<text><paragraph>Vomiting, diarrhea, nausea, anorexia, dryness
of mouth, hypersecretion, increased motility, increased salivation.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="5D3CBB63-301D-5072-64AD-420843734161" />
<title mediaType="text/x-hl7-title+xml">Hemic and Lymphatic System</title>
<text><paragraph>Thrombocytopenic purpura.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="B812868E-CABF-BD32-A6F0-4CB34A0EEEDE" />
<title mediaType="text/x-hl7-title+xml">Metabolic and Nutritional Disorders</title>
<text><paragraph>Weight gain.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="F120DE9C-291E-A00D-0F29-29388C69B713" />
<title mediaType="text/x-hl7-title+xml">Musculoskeletal System</title>
<text><paragraph>Muscular aches.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="94DE9D5E-1F17-772A-B1DB-D9C65B9F5D23" />
<title mediaType="text/x-hl7-title+xml">Nervous System</title>
<text><paragraph>Rare parkinsonian syndrome and other extrapyramidal
tract symptoms, dizziness, paradoxical anxiety, depression, nervousness, nightmares,
dull sensorium, drowsiness, decreased libido.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="841FEBFF-E590-08FB-259E-E1AF65F09526" />
<title mediaType="text/x-hl7-title+xml">Respiratory System</title>
<text><paragraph>Asthma in asthmatic patients, dyspnea, epistaxis,
nasal congestion.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="2F23445E-629C-A5B1-B0EA-71ED2E8E208E" />
<title mediaType="text/x-hl7-title+xml">Skin and Appendages</title>
<text><paragraph>Rash, pruritus, flushing of skin.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="A61A9218-043F-301F-E316-3D9A20CFB5B2" />
<title mediaType="text/x-hl7-title+xml">Special Senses</title>
<text><paragraph>Deafness, optic atrophy, glaucoma, uveitis, conjunctival
injection.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="97EB5DA1-9594-7633-1E04-4F877A2A663C" />
<title mediaType="text/x-hl7-title+xml">Urogenital System</title>
<text><paragraph>Nonpuerperal lactation, impotence, dysuria, gynecomastia,
breast engorgement.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="54F8745A-288A-E482-88D5-6219ACA138E1" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE section" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>Symptoms of thiazide overdosage include electrolyte
imbalance and signs of potassium deficiency such as confusion, dizziness,
muscular weakness, and gastrointestinal disturbances.  General supportive
measures including replacement of fluids and electrolytes may be indicated
in treatment of overdosage.</paragraph><paragraph>An overdosage of
deserpidine is characterized by flushing of the skin, conjunctival injection,
and pupillary constriction.  Sedation ranging from drowsiness to coma may
occur.  Hypotension, hypothermia, central respiratory depression, and bradycardia
may develop in cases of severe overdosage.  Treatment consists of the careful
evacuation of stomach contents followed by the usual procedures for the symptomatic
management of CNS depressant overdosage.  If severe hypotension occurs, it
should be treated with a direct-acting vasopressor (e.g., norepinephrine). 
If bradycardia becomes marked, especially with cardiac arrhythmia, consider
use of atropine or other anticholinergic drug.  Because of prolonged effects
of deserpidine, the patient should be closely observed for at least 72 hours.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="0A175928-9D92-64F7-7C81-F61E13809B02" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION section" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph>Dosage should be determined by individual titration
of ingredients (see <content styleCode="bold">BOXED WARNING</content>).</paragraph><paragraph>Dosage of both components should be carefully adjusted to
the needs of the individual patient.  Since at least 10 days to 2 weeks may
elapse before the full effects of the drugs become manifest, the dosage of
the drugs should not be adjusted more frequently.</paragraph><paragraph>Two
tablet strengths, ENDURONYL (methyclothiazide 5 mg, deserpidine 0.25 mg) and
ENDURONYL FORTE (methyclothiazide 5 mg, deserpidine 0.5 mg), each grooved,
are provided to permit considerable latitude in meeting the dosage requirements
of individual patients.</paragraph><paragraph>The following table will
help in determining which dose of ENDURONYL or ENDURONYL FORTE tablets best
represents the equivalent of the titrated dose.</paragraph><table ID="table_1" border="0" frame="below" width="100%"><colgroup>
<col width="34%" />
<col width="32%" />
<col width="32%" />
</colgroup>
<thead>
<tr valign="bottom"><td align="center"><content styleCode="bold">Daily Dosage of ENDURONYL</content></td><td align="center"><content styleCode="bold">Methyclothiazide</content></td><td align="center"><content styleCode="bold">Deserpidine</content></td></tr>
</thead>
<tbody>
<tr><td align="center">&#189; tablet</td><td align="center">2.5 mg</td><td align="center">0.125 mg</td></tr>
<tr><td align="center">1 tablet</td><td align="center">5.0 mg</td><td align="center">0.250 mg</td></tr>
<tr><td align="center">1&#189; tablets</td><td align="center">7.5 mg</td><td align="center">0.375 mg</td></tr>
<tr><td align="center">2 tablets</td><td align="center">10.0 mg</td><td align="center">0.500 mg</td></tr>
</tbody>
</table><table ID="table_2" border="0" frame="below" width="100%"><colgroup>
<col width="41%" />
<col width="29%" />
<col width="29%" />
</colgroup>
<thead>
<tr valign="bottom"><td align="center"><content styleCode="bold">Daily Dosage of ENDURONYL
FORTE</content></td><td align="center"><content styleCode="bold">Methyclothiazide</content></td><td align="center"><content styleCode="bold">Deserpidine</content></td></tr>
</thead>
<tbody>
<tr><td align="center">&#189; tablet</td><td align="center">2.5 mg</td><td align="center">0.250 mg</td></tr>
<tr><td align="center">1 tablet</td><td align="center">5.0 mg</td><td align="center">0.500 mg</td></tr>
<tr><td align="center">1&#189; tablets</td><td align="center">7.5 mg</td><td align="center">0.750 mg</td></tr>
<tr><td align="center">2 tablets</td><td align="center">10.0 mg</td><td align="center">1.000 mg</td></tr>
</tbody>
</table><paragraph>The appropriate dose of ENDURONYL tablets is administered
orally, once daily.  The usual adult dosage is one lower-strength ENDURONYL
tablet daily.  Debilitated and elderly patients may require lower doses.</paragraph><paragraph>There is no contraindication to combining ENDURONYL tablets
with other antihypertensive agents.  When other antihypertensive agents are
to be added to the regimen, this should be accomplished gradually.  Ganglionic
blocking agents should be given at only half the usual dose since their effect
is potentiated by pretreatment with ENDURONYL tablets.  </paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="DF9E0D5A-CCB9-3808-9AF4-CB3B94FC371D" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED section" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>ENDURONYL (methyclothiazide and deserpidine) is supplied
as monogrammed, grooved, square-shaped tablets in the following dosage sizes
and quantities:</paragraph><paragraph>ENDURONYL (5 mg of methyclothiazide
and 0.25 mg of deserpidine) yellow tablets bearing the <content styleCode="bold">Abbott&#8220;A&#8221; logo</content> and Abbo-Code LS for product identification
in bottles of 100 (<content styleCode="bold">NDC</content>&#160;0074-6838-01).</paragraph><paragraph>ENDURONYL FORTE (5 mg of methyclothiazide and 0.5 mg of deserpidine)
gray-colored tablets bearing the <content styleCode="bold">Abbott &#8220;A&#8221;
logo</content> and Abbo-Code LT for product identification in bottles of 100
(<content styleCode="bold">NDC</content> 0074-6854-01).</paragraph></text>
<effectiveTime value="20060510" />
<component>
<section>
<id root="F3057B0B-C5BC-E130-D182-1060E2864A8B" />
<title mediaType="text/x-hl7-title+xml">Recommended Storage</title>
<text><paragraph>Store below 86&#176;F (30&#176;C).</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
<component>
<section>
<id root="D505A757-F481-4C25-670E-81635CAD7AF3" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph>Abbott Laboratories</paragraph><paragraph>North Chicago,
IL 60064, U.S.A.</paragraph><paragraph>Printed in U.S.A.</paragraph></text>
<effectiveTime value="20060510" />
</section>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
